Market Place
Sourcing Support
Intensity Therapeutics Selected for Oral Presentation at CTOS 2024
08 Nov 2024 //
PR NEWSWIRE
Intensity Therapeutics Appoints Thomas Dubin To Board Of Directors
15 May 2024 //
PR NEWSWIRE
Intensity Therapeutics Provides Update on Progress of Ph 3 Sarcoma Program
03 Jan 2024 //
PR NEWSWIRE
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
12 Dec 2023 //
PRESS RELEASE
Intensity Therapeutics Presents Positive INT230-6 Data at the 2023 SABCS
08 Dec 2023 //
PRESS RELEASE
Intensity Selected for Spotlight Oral Presentation at the 2023Cancer Symposium
01 Dec 2023 //
PRESS RELEASE
Intensity Therapeutics Presents Positive INT230-6 Data in Patients
02 Nov 2023 //
PR NEWSWIRE
Intensity Therapeutics Reports Second Quarter Financial Results
14 Aug 2023 //
PR NEWSWIRE
Cancer biotech Intensity Therapeutics looks to pull in $16M+ IPO
30 Jun 2023 //
ENDPTS
Intensity Reports INT230-6 Can Cause Immune Priming in Quiescent Breast Cancers
06 Jun 2023 //
PR NEWSWIRE
Intensity`s INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab
03 Jun 2023 //
PR NEWSWIRE
Intensity Reports Use of INT230-6 Alone or Combination with Ipilimumab Shows
18 Nov 2022 //
PRNEWSWIRE
Intensity`s INT230-6 Shows Increased Survival as Mono/Comb. with Pembrolizumab
03 Jun 2022 //
PRNEWSWIRE
Intensity Therapeutics to Participate in the 34th Annual Roth Conference
09 Mar 2022 //
PRNEWSWIRE
Intensity Therapeutics cuts range by 30% to $6 to $8 ahead of $15M IPO
08 Dec 2021 //
RENAISSANCECAPITAL
Intensity Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows
13 Nov 2021 //
PRNEWSWIRE
Intensity`s Data on INT230-6 Accepted for Presentation
03 Nov 2021 //
PRNEWSWIRE
Solid tumor biotech Intensity Therapeutics files for a $17 million IPO
29 Oct 2021 //
RENAISSANCECAPITAL
Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 ASCO
20 May 2021 //
BUSINESSWIRE
Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer
24 Mar 2021 //
PRESS RELEASE
Intensity Reports Favorable Data of INT230-6 from the Ongoing Ph1/2 Study
11 Nov 2020 //
BIOSPACE
Intensity Therapeutics Doses First Patient with Combination of INT230-6
17 Sep 2020 //
INTENSITY THERAPEUTICS
Intensity Therapeutics Doses First Patient with Combination
16 Sep 2020 //
BUSINESSWIRE
Intensity Announces Publication of Research INT230-6 Demonstrates Tissue
25 Jun 2020 //
PRESS RELEASE
Intensity Therapeutics Announces Publication of of INT230-6
24 Jun 2020 //
BUSINESSWIRE
Intensity Therapeutics’ Abstract (#3016) Selected for Oral PresentationASCO 2020
20 Jun 2020 //
PRESS RELEASE
Intensity ’ Abstract (#3016) Selected for Oral Presentation as Part of a Poster
20 May 2020 //
BUSINESSWIRE
Intensity Therapeutics Signs Clinical Collaboration Agreement with BMY`s
14 Apr 2020 //
BUSINESSWIRE
Intensity Therape. Reports Safety Results from First Cohort of the KEYNOTE A10
30 Mar 2020 //
BUSINESSWIRE
Intensity`s to Present Data on Safety, Tumor Regression INT230-6
16 May 2019 //
BUSINESSWIRE
